Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.

Wojciech KrajewskiMarco MoschiniJoanna ChorbińskaŁukasz NowakSławomir PoletajewAndrzej TukiendorfLuca AfferiJeremy Yuen-Chun TeohTim MuilwijkSteven JoniauAlessandro TafuriAlessandro AntonelliFrancesco CianfloneAndrea MariEttore Di TrapaniKees HendricksenMario Alvarez-MaestroAndrea Rodríguez-SerranoGiuseppe SimoneStefania ZamboniClaudio SimeoneMaria Cristina MarconiRiccardo MastroianniGuillaume PloussardEkaterina LaukhtinaKarl TullyAnna KołodziejJoanna KrajewskaRadosław PiszczekEvanguelos XylinasRomuald Zdrojowynull null

Published in: World journal of urology (2020)

This study shows that delaying BCG immunotherapy after TURB of T1HG NMIBC is associated with an increased risk of tumor recurrence and progression.

Keyphrases

muscle invasive bladder cancer
emergency department
fluorescent probe
free survival
living cells